SheppHeartCABG trial-comprehensive early rehabilitation after coronary artery bypass grafting: a protocol for a randomised clinical trial.

INTRODUCTION: Patients undergoing coronary artery bypass graft surgery often experience a range of symptoms. Studies indicate that non-pharmacological interventions such as exercise training and psychoeducation have a positive physiological and psychological effect in early outpatient rehabilitation. The SheppHeartCABG trial will investigate the effect of early comprehensive rehabilitation in early phase rehabilitation versus usual care. The aim of this paper is to present the protocol for the SheppHeartCABG trial. METHODS/ANALYSIS: SheppHeartCABG is an investigator-initiated randomised clinical superiority trial with blinded outcome assessment, employing 1:1 central randomisation to rehabilitation plus usual care versus usual care alone. On the basis of a sample size calculation, 326 patients undergoing coronary artery bypass grafting will be included from two clinical sites. All patients receive usual care and patients allocated to the experimental intervention follow 4 weeks rehabilitation consisting of an exercise programme, psycho-educative consultations and a compact mindfulness programme. The primary outcome is physical function measured by the 6-min walk test. The secondary outcomes are mental health and physical activity measured by the Medical Outcome Study Short Form (SF-12), anxiety and depression measured by the Hospital Anxiety and Depression Scale questionnaire, physical, emotional and global scores by the HeartQoL questionnaire, sleep measured by the Pittsburgh Sleep Quality Index, pain measured by the Örebro Musculoskeletal Screening Questionnaire and muscle endurance measured by the sit-to-stand test. A number of explorative analyses will also be conducted. ETHICS AND DISSEMINATION: SheppHeartCABG is approved by the regional ethics committee (no. H-4-2014-109) and the Danish Data Protection Agency (no. 30-1309) and is performed in accordance with good clinical practice and the Declaration of Helsinki in its latest form. Positive, neutral and negative results of the trial will be submitted to international peer-reviewed journals. Furthermore, results will be presented at national and international conferences relevant to the subject fields. TRIAL REGISTRATION NUMBER: NCT02290262; pre-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

RCT Entities:   Population Interventions Outcomes

This study has been designed to meet the criteria for high quality in a non-pharmacological randomised clinical trial with computer-generated randomisation, multicentre participation and blinded outcome assessment and analysis.

We are aware of the subjective nature of the self-reported secondary outcomes. Accordingly, we will interpret data conservatively.

This trial is the first larger trial testing the effects of a phase I comprehensive cardiac rehabilitation programme after coronary artery bypass graft surgery.

Background

Following coronary artery bypass grafting (CABG), patients often experience a range of symptoms caused by the surgical procedure and the ischaemic heart disease and the subsequently return to everyday life is often prolonged.1 Symptoms of anxiety and depression peak before heart surgery and again 2 weeks after and may persist up to 4 months after discharge.2 Pain, fatigue and sleep disorders are common symptoms after CABG and may be partly due to the lack of postoperative physical activity.1 3 4 To tackle these issues, cardiac rehabilitation is recommended.5

Cardiac rehabilitation programmes are generally described according to three main phases: inpatient (phase I), early outpatient (phase II) and long-term outpatient cardiac rehabilitation (phase III).6 Rehabilitation phase I normally ends 4 weeks following CABG and ought to be followed by rehabilitation phase II.6 Enrolment in cardiac rehabilitation after coronary revascularisation positively impacts the psychological status of patients and reduces cardiovascular mortality.7 More specifically, physical exercise in rehabilitation phase II has positive effects on quality of life, exercise capacity, coronary blood vessels, the myocardium, the endothelial function and coagulation.8–13 There are no randomised clinical trials assessing cardiac rehabilitation programmes in phase I.

Non-pharmacological treatment potential

Open heart surgery is a severe physical and mental strain. Indeed, cardiopulmonary bypass has a temporary negative effect on physical functions.8 9 However, studies show that psychosocial factors are also vital for patients’ prognosis in the short and longer term.10 The interventions in phase I rehabilitation after CABG have either investigated the physical or the psychological perspective. The effect of respiratory exercise preoperatively and in the early postoperative period after CABG surgery has been examined using different techniques.11–14 Trials generally indicate a clinically significant effect of respiratory physiotherapy, but these trials are small and include selected trial populations. Cardiopulmonary bypass has a temporary negative effect on the physical function level.8 9 Examination of anxiety and depression in the postoperative period is needed due to the limited power and the use of non-validated instruments in the studies.2 Furthermore, it has been shown that a combination of a psycho-educative intervention plus physical exercise has a positive effect on physical and mental self-related health.15 16 Mindfulness is a form of psychosocial intervention that offers stress reduction, calm accepting awareness and support of self-care through meditation-based exercises. Until now, trials of mindfulness have not been conducted in the context of CABG patients but several trials with cardiovascular patients in other contexts have shown reduction of perceived stress, pain, depression, sleeping problems and anxiety.17–20

International guidelines recommend early mobilisation during hospitalisation, outpatient exercise training and patient education after CABG.21 Since the symptoms related to CABG include a physical and a psychological component, it is plausible that patients with CABG benefit from a comprehensive rehabilitation intervention.22 The SheppHeartCABG pilot trial was initiated in 2013 to test the safety and tolerability of a comprehensive intervention and to provide outcome data for designing a larger trial.23 The pilot trial included 60 patients and indicated the feasibility of physical and psycho-educational cardiac rehabilitation in addition to sufficient inclusion rate and high compliance with most elements.23 The results were used to modify the rehabilitation programme and optimise the protocol and targeted outcomes.

In summary, there is evidence that physical exercise benefits heart patients’ rehabilitation associated with open heart surgery. This part normally begins 2–4 weeks after discharge, and the effects of early action are not known. In addition, the positive effect of rehabilitation may be stronger when physical exercise is combined with a psychological intervention component.

Trial objectives

The objective of the SheppHeartCABG trial is to investigate the benefits and harms of a phase I comprehensive cardiac rehabilitation programme consisting of an exercise training component and a psycho-educative component, in addition to usual treatment in patients with CABG. The primary hypothesis is that a comprehensive rehabilitation programme improves the functional level measured by a 6-min walk test (6MWT) by 30 m in the experimental group compared with the control group. The estimated increase in the primary outcome is a conservatively expected estimate based on the SheppHeartCABG pilot trial, where we found a mean of 548 m in the intervention group receiving physical training and psycho-education versus a mean of 451 m in the control group measured by 6MWT.23 The secondary hypotheses are that a comprehensive rehabilitation programme will improve: quality of life, sleep disorder, pain, anxiety, depression and leg strength and endurance. Exploratory analyses will evaluate whether the intervention will have a positive impact on: fatigue, physical activity, cognitive and emotional representation of illness and self-rated health.

Methods

SheppHeartCABG is an investigator-initiated randomised clinical superiority trial with a blinded outcome assessment, employing 1:1 randomisation to a comprehensive cardiac rehabilitation programme plus usual care versus usual care alone. Patients will be recruited from two university hospitals in Denmark. Figure 1 shows the trial design.

Figure 1

Trial design. CABG, coronary artery bypass grafting; HADS, Hospital Anxiety and Depression Scale; NYHA, New York Heart Association; PSQI, Pittsburgh Sleep Quality Index.

Trial population and eligibility criteria

Patients aged 18 years and older admitted for elective CABG who speak and understand Danish, and provide written informed content, are considered eligible for participation. Exclusion criteria are patients at intermediate or high risk in relation to their cardiovascular status24 and patients with orthopaedic conditions that would prohibit walking and cycling exercise.

Experimental intervention

The experimental intervention is a comprehensive rehabilitation programme with an exercise training component and a psycho-educational component from admission until 4 weeks after CABG surgery.

The physical components

The exercise programme during hospitalisation consists of respiratory physiotherapy, neck and shoulder exercises, walking and cycling. The purpose is preventing respiratory complications such as atelectasis and pneumonia, neck and shoulder pain and increasing the physical functional level. Each exercise in the training programme is based on guidelines,25 public health recommendations for physical activity for adults26 and supported by European recommendations for physical training in patients with cardiac disease.21 27 Physical exercise starts immediately after surgery and follows the ACSM’s Guidelines for Exercise Testing and Prescription.25 A physiotherapist with specific knowledge of open heart surgery and cardiac rehabilitation initiates the programme and gives the participants standardised instructions in each part of the programme. All the completions of exercises are documented in the training diary.

Physical exercises during hospitalisation

Breathing exercise

This consists of 7–10 deep breaths four times each day when awake in daytime. Begin at admission and continue until hospital discharge.

Peak flow spirometry

Participants are encouraged to perform breathing exercises consisting of 3–5 min of breathing in the PEP-flute four times daily during postoperative days 1 through 4.

Walking

Walking exercises are performed in the hallway at the hospital ward on postoperative day 1 continuing to 4 weeks postsurgery. Walking exercise begins on the first postoperative day with a 2×5 min walk; second postoperative day a 2×7 min walk; third postoperative day a 3×7 min walk and from the fourth postoperative day until discharge a 3×10 min walk. The participant has to increase the intensity of walking from low to moderate during hospital admission.

Neck and shoulder

This consists of shoulder lifts, shoulder rolls and head rolls with 10 sessions of each exercise two times per day from postoperative day 1 until hospital discharge.

Cycling

Cycling exercise training is conducted on stationary bicycles or alternatively using bed bikes.28 Heart rate and saturation are monitored at three scheduled times during the two first exercise sessions. The participants are encouraged to train using moderate intensity, so that they are not exhausted and the training is safe and has effect.29 Time for cycling will be 10 min. The rating of perceived exertion scales (RPE) is used to measure the exercise intensity. The cycling exercise intensity is at RPE Borg between 13 and 15 on a scale of 6–20,30 and the power on the cycle is programmed so that it matches this intensity. There will be a 5 min warm-up and a 5 min cool-down to achieve cardiovascular adjustment with exercise intensity ≤10 RPE Borg.31 32 The cycling exercise consists of two daily sessions from the third postoperative day until discharge.

Physical exercise from discharge to 4 weeks after surgery

Exercise training will take place at the participants’ home and outdoors including resistance training and walking to obtain muscle strength and physical capacity.33 At hospital, the physiotherapist introduces the exercises and the training diary.

The length of daily walk will be increased from hospital discharge until 4 weeks as follows: 3×10 min, 2×15 min, 2×20 min, 2×25 min and 2×30 min. The walking intensity is moderate: the first 2–3 min ≤10–13 on the Borg Scale and the last 2–3 min at the same intensity level and the time between 12 and 14 on the Borg Scale.

Leg endurance and strength

The participants perform a sit and stand exercise and ‘up on toes’ with 10 repetitions two times per day from hospital discharge until 4 weeks after CABG.

The psycho-educational components

The interventions consist of four consultations: admission day, second postoperative day, discharge and 3 weeks after CABG. The first three consultations are in-hospital, and the fourth is by phone. The psycho-educative intervention has two parts: one inspired by the three dimensions in Rosemarie R Parse's ‘Human Becoming Practice Methodologies’34 and the second is a compact mindfulness programme combing dialogue and recorded instructions for individual practice.35 The overall goal of the psycho-educative intervention is that the patients learn to construe and react to relevant physical and psychological symptoms and thus learn to cope with anxiety and fear after CABG.

Consultations

Four consultations are scheduled: admission day, second postoperative day, discharge and 3 weeks after CABG. The first three consultations are in-hospital, and the fourth is by phone. The consultations are conducted by specially trained nurses and last for about 45 min. Rosemarie R Parse's ‘Human Becoming Practice Methodologies’34 forms the conceptual foundation for the dialogues with the patients.

The Human becoming Practice Method describes three dimensions for dialogue: (1) discuss and give meaning to the past, present and future; (2) explore and discuss events and opportunities and (3) pursue imagined possibilities. According to this method, there are three ways to make health changes: (1) using creative images to explore, (2) recognising personal patterns and (3) value priorities and shed light on the paradoxes by looking at the incongruence in a situation and change the view of reality. The nurse is ‘truly present’ in the process through discussion, silent immersion and reflection.

Mindfulness

The other part of the psycho-educational intervention is a set of mindfulness exercises that patients can use ad libitum for stress reduction, calm awareness and self-care through meditation-based exercises.17 36 For this trial, a brief mindfulness intervention with several components has been developed in cooperation with the Center for Research in Existence and Society, University of Copenhagen. It particularly focuses on the patients with CABG in need of calming down in physically and emotionally stressful situations. At the first consultation, participants are introduced to mindfulness through a short mindfulness exercise lead by the nurse, followed by a dialogue. The participants receive an mp-3 player with an audio mindfulness programme. The audio mindfulness programme consists of three guided meditations of 5 min, 15 min and 20 min, and the participants are encouraged to listen to all three meditations from admission to 4 weeks after CABG.

Usual care

Patient in both arms of the trial receive usual care according to the guidelines.6 37 The standard admission time after CABG is 5–8 days. Usual treatment involves preoperative and postoperative information provided by physicians, nurses and physiotherapists. Instructions regarding precautions after sternotomy are provided by physiotherapists covering the immediate postoperative period during hospitalisation and after discharge. Primary perioperative nursing consists of admission interview with preoperative screening (falls, nutrition); introduction to postoperative pain and nausea medications; pain assessment and postoperative activities. Early postoperative care focuses on the observation of vital signs, while the remainder of the hospital admission focuses on recovery and preparation for discharge.

Outcomes and data collection

Data will be collected at admission, discharge and 4 weeks following surgery (see table 1).

Table 1

SheppHeartCABG: demographic and baseline characteristics, tests and questionnaires

Quantity	Time of measure	Type of quantity
Demographic
Age, height, weight, martial, educational	Baseline	Continuous
Occupational status	Baseline	Categorical
Smoking	Baseline	Binary (Y/N)
Clinical
Nutritional status (BMI)	Baseline	Continuous
NYHA calcification	Baseline	Continuous
Type of heart disease	Baseline	Categorical
Diabetes mellitus	Baseline	Binary (Y/N)
Medical status	Baseline	Categorical
Level of physical activity	Baseline, discharge, W4	Continuous
Functional level
6MWT and Sit and stand test	Baseline, discharge, W4	Continuous
Questionnaire
SF 12, HADS, ÖMPSQ, B-IPQ, EQ-5D	Baseline, discharge, W4	Continuous
HeartQol, PSQI, MFI-20, IPAQ	Baseline, W4	Continuous

BMI, body mass index; HADS, Hospital Anxiety and Depression Scale; 6MWT, 6-min walk test.

Primary outcome

The primary outcome in this trial is physical functional level as measured by the 6MWT. 6MWT is a simple tool and will be administered at admission, discharge and 4 weeks following CABG.38 For the 6MWT, the participants walked up and down a 30 m hallway for 6 min according to the guidelines.39 To ensure standard testing, a standardised instruction for patients has been developed.

Secondary outcomes

Furthermore, we will assess nine preplanned secondary hypotheses based on estimates using the SDs from the SheppHeartCABG pilot trial.23 The variables, instruments, subscales, Cronbach’s α and hypothesised differences are detailed in table 2.

Table 2

Overview of secondary outcomes

Variables	Instrument	Subscales	Cronbach’s alpha	Hypothesised difference (anticipated power)
Health status	Medical Outcome Study Short Form 12 (SF-12)	Physical Component Summary (PCS) [0–100]Mental Component Summary (MCS) [0–100]	0.870.84	2.4 (97%)8.21(100%)
Anxiety—depression	Hospital Anxiety and Depression Scale (HADS)41 42	HADS-A scale [0–21]HADS-D scale [0–21]	0.830.82	1.26 (86%)4.3 (100%)
Quality of life	HeartQol questionnaire43 57	The emotional subscales [0–3]The global subscales [0–3]	0.80–0.910.80–0.91	0.3 (85%)0.2 (95%)
Sleep	Pittsburgh Sleep Quality Index (PSQI)58	Component 1: Subjective sleep quality score [0–3]Component 2: Sleep latency score [0–3]Component 3: Sleep duration score [0–3]Component 4: Habitual sleep efficiency score [0–3]Component 5: Step disturbances score[0–3]Component 6: Use of sleeping medication score[0–3]Component 7: Daytime dysfunction score [0–3]Global PQSI score [0–21]	0.83	2.2 (96%)
Pain	Örebro Musculoskeletal Pain Questionnaire (OMPQ)44	OMPQ total score [0–210]	0.86	10.2 (98%)
Strength and endurance in legs	Sit-to-stand test39	Total number of repetitions	NR	3.6 (100%)

HADS, Hospital Anxiety and Depression Scale; NR, not reported.

The Medical Outcome Study Short Form 12 (SF-12)

Mental health and physical health are measured by the Medical Outcome Study Short Form 12 (SF-12) 4 weeks after surgery. The SF-12 is a 12-item validated version of the SF-36 and is a brief, reliable measure of overall health status that generates a physical component score and a mental component score (PCS and MCS).40

The Hospital Anxiety and Depression Scale

This 14-item instrument measures symptoms of anxiety and depression41 42 The scale offers two scores HADS-A and HADS-D, each of which can range from 0 to 21. Scores of 0–7 for either subscale are regarded as normal; 8–10 suggest the presence of a mood disorder and 11 and above suggest the probable presence of a mood disorder.

The HeartQol Questionnaire

Health-related quality of life is measured with the use of the HeartQol questionnaire.43 The emotional subscale and the global scale will be included which are scored from 0 to 3. The questionnaire consists of 14 items.

The Pittsburgh Sleep Quality Index

This is a self-rated questionnaire which assesses quality and disturbances of sleep over a 1-month time interval. Nineteen items generate seven component scores. The sum of scores for these seven components yields one global score.

The Örebro Musculoskeletal Screening Questionnaire

Pain is measured by the Örebro Musculoskeletal Screening Questionnaire. This 25-item self-administered questionnaire is formulated such that all musculoskeletal pains are addressed and assessed in five categories.44

Sit-to-stand test

Strength and endurance in legs is measured by a sit-to-stand test 4 weeks following surgery.45 The test is carried out using a chair. The participants are then seated on the chair and have to get up to full standing position and then return to the initial seated position as many times as possible in 30 s. The test will be performed in accordance with guidelines.46

Exploratory outcomes

Clinical and demographic data will be evaluated. The HeartQol physical component will be analysed as an exploratory outcome.43 Furthermore, a series of questionnaires regarding fatigue, physical activity and perception of illness are administered. The Measurement of Fatigue Instrument47–50 is a 20 item self-report instrument designed to measure fatigue. The International Physical Activity Questionnaire51 is used to measure health-related physical activity. Perception of illness is measured by The Brief perception Questionnaire,52 which is a short questionnaire that assesses cognitive and emotional representations of illness on the basis of eight items. The EQ-5D is a standardised instrument for use as a measure of current health status that provides a simple descriptive profile and a single index value that can be used in clinical and economic evaluation of healthcare and in population health surveys.53

Sample size and power calculations

The study is a randomised superiority trial with the continuous outcome 6MWT with 1 control per experimental participant. In the pilot trial, the outcome was normally distributed with an SD of 90 m. If the true difference in the experimental and control means is 30 m, the trial shall include 163 experimental participants and 163 control participants (total participants 326) to be able to reject the null hypothesis that the population means of the experimental and control groups are equal with probability (power) 85%. The type I error probability associated with this test of this null hypothesis is 5%.

Based on SheppHeartCABG the pilot trial, several of the secondary outcomes are overpowered as shown previously. For all outcomes except HeartQol physical, the power to reject the null hypothesis was above 85% (type I error 5%) (see table 2).

Study procedure and randomisation

To achieve our estimated sample size of 326 participants, patients will be identified and screened consecutively from the current elective CABG waiting list. Patients similar to the New York Heart Association (NYHA) groups I–III and without physical illness which prevents physical exercise are suitable participants in the trial. Verbal information will be given to the patient on admission day and is planned so it is possible for relatives to participate by staff personal. If a patient accepts to participate after verbal and written informed consent, the patient is randomised to the rehabilitation plus usual care or usual care alone. The allocation sequence is computer generated with a varying block size concealed by the investigators. The allocation will be conducted centrally using the web-based ‘Copenhagen Trial Unit Online Randomisation System’, and selected relevant participant information will be registered (civil registration number (CPR), participant number and stratum). Stratification variables are Rigshospitalet, University of Copenhagen and Odense Universitetshospital, University of Southern Denmark and sex. After allocation, the investigator immediately informs the patient of the result and the further plan. For both groups, follow-up assessments including physical tests and questionnaires will take place at admission, discharge and 4 weeks following surgery. Questionnaires will be completed on paper or electronically in the questionnaire system Enalyzer. Data management is handled independently from the researchers who interpret the data. All data are stored electronically in a coded database and in an independent spreadsheet, which is only accessible by the SheppHeart staff. The recruitment process will continue until 326 patients have been included.

Blinding

It is not possible to blind the interventions to the staff and patients. However, all physical tests, data collection and data management will be conducted by staff blinded to the interventions. Statistical analyses and drawing of conclusions from these will also be conducted blinded to the intervention group.

Statistical analysis

Analysis of primary and secondary outcomes

The primary and all secondary outcomes are continuous. For all primary and secondary outcomes except HeartQol and HADS, it is expected that the scores will be normally distributed.

Analyses will be intention-to-treat analyses using two-sided tests with a significance level of 5%. There are two types of comparison between the intervention groups: (1) comparison of values measured at week 4 and (2) comparison of values measured at discharge and at 4 weeks. In the first type, a general univariate linear model is used (except for HeartQol and HADS (see below)), adjusted for baseline values. In the second type (except for HeartQol and HADS (see below)), a mixed linear model including an unstructured covariance matrix is used. In this model, the interaction between intervention and time is of main interest. If assumptions of the models are not fulfilled with reasonable approximation, non-parametric sensitivity tests will be performed.

HeartQol quantities are converted to binary quantities based on the median score, and logistic regression is used to compare the two groups at 4 weeks adjusted for value at baseline. HADS is reported as mean (SD) and is converted to binary quantities expressed as probable anxiety and depression (scores≥8). Logistic regression is used to compare the intervention and control groups at 4 weeks adjusted for value at baseline.

Since almost all secondary outcomes are overpowered, Cohen's d will be calculated for each outcome to test the clinical effect. SAS V.9.3 will be used.

Missing values and multiplicity

For the primary and secondary outcomes, multiple imputation (MI) of missing values using the Markov Chain Monte Carlo (MCMC) approach will be performed if the number of incomplete participants is above 5%. The variables included are the group membership, stratifying variables (site and sex), time (baseline, discharge and 4 weeks after discharge) and outcomes. If MI is used, the primary result will be that based on the multiply imputed data sets. Significant (adjusted p<0.05) results of the primary and secondary outcomes will be supplemented by the following worst case sensitivity analysis. Let A be the group where a beneficial significant effect is observed and B be the other group. Missing values in group A will be imputed by the minimum value found in the material, and missing values in group B will be imputed by the maximum value found. When the treatment code is broken, the results may be interpreted.

The primary outcome (6MWT) will first be tested using a significance level of 0.05. Analyses of the secondary outcome measures as preplanned in the protocol will be analysed with no adjustment of p values due to multiplicity. Instead, the interpretation of each secondary outcome measure will be assessed in the light of multiple testing, that is, statistically significant effects will be interpreted in the context of increased risk of type-I error. No significance testing will be performed for the explorative outcomes.

In addition to the primary intention-to-treat analysis, we will also perform a per-protocol analysis to include information on adherence to the intervention in the intervention group.54 The per-protocol definition reflects the two components of the intervention, in that patients in the intervention group must have completed 75% per cent of the programme in the per-protocol analysis.

Ethics, safety and dissemination

The trial will be conducted according to the latest Declaration of Helsinki. It has been registered at ClinicalTrials.gov no NCT02290262 before inclusion of the first participant. Information about the trial is given verbally and in writing. Eligible patients will be enrolled as trial participants. Trial participants are free to withdraw their informed consent at any time and will be treated according to the department's standard procedures. Patients who leave the trial will be asked for permission to continue to collect data and to use already collected data. If the patient gives permission, data will be included in the final analysis. If a patient refuses the use of already collected data, all related data will be destroyed. The trial will be conducted according to Act. No. 593 of 14 June 2011 on Act on Research Ethics Review of Health Research Projects. The investigator will immediately notify the regional ethics committee if, within the interventions period, there occur serious adverse events or serious adverse reactions. An independent Data Monitoring and Safety Committee (DMSC) has been established.

Safety

Throughout the trial, annual reports including all expected or unexpected adverse events or reactions will be submitted to the ethical committee. Reports will be accompanied by an assessment of the participants’ safety. The investigator notifies the committee within 90 days of completion of the trial.

Dissemination plan

Positive, neutral and negative results of the trial will be submitted to international peer-reviewed journals. Furthermore, results will be presented at national and international conferences relevant to the subject fields. Authorship will be allocated using the guidelines for authorship defined by the International Committees of Medical Journal Editors and depends on personal involvement. Ethic Committees and component authorities will be able to obtain direct access to data and documentation.

Discussion

This SheppHeartCABG trial, assessing the effect of a comprehensive cardiac rehabilitation in phase I rehabilitation on a population undergoing CABG, is the first randomised clinical trial in a representative population. This trial is expected to contribute results that can improve patient outcomes related to ischaemic heart disease treated by CABG and early rehabilitation. This is the first trial to test the effect of a comprehensive rehabilitation programme in rehabilitation phase I after CABG. SheppHeartCABG has been designed to meet the criteria for high quality in a non-pharmacological clinical trial with central stratified randomisation and two centre participation which secures against selection bias.55 56

The primary outcome and all statistical analysis are blinded to intervention, which should reduce detection and interpretation bias.55 56

Trajectory

Inclusion was initiated on November 2014 and is expected to continue until July 2016.